[{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"2d85f8bd-c4cc-4fe8-bf91-8467d2481477","acronym":"REBECCA","url":"https://clinicaltrials.gov/study/NCT06856343","created_at":"2025-06-07T15:03:07.425Z","updated_at":"2025-06-07T15:03:07.425Z","phase":"","brief_title":"REBECCA Real-world Early BrEast CanCer mAnagement","source_id_and_acronym":"NCT06856343 - REBECCA","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/30/2024","start_date":" 12/30/2024","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-05-06"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"aae6b561-f8a6-4a7b-8a1a-ca992b0769d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006421","created_at":"2021-01-17T23:53:44.292Z","updated_at":"2025-02-25T13:38:43.830Z","phase":"","brief_title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","source_id_and_acronym":"NCT00006421","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/25/2000","start_date":" 10/25/2000","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"4cc7d5ae-d434-4c5a-bf92-880e3c64f923","acronym":"NCI-2016-01130","url":"https://clinicaltrials.gov/study/NCT02849496","created_at":"2021-01-18T13:59:18.008Z","updated_at":"2025-02-25T13:52:10.914Z","phase":"Phase 2","brief_title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","source_id_and_acronym":"NCT02849496 - NCI-2016-01130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TMB • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA mutation","tags":["HER-2 • TMB • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-20"},{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"ST316-101","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2025-02-25T14:17:54.068Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739 - ST316-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-17"},{"id":"48f5abe6-9ec9-4e35-ad4a-60d366e60af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598257","created_at":"2021-01-18T17:41:27.688Z","updated_at":"2025-02-25T14:15:11.919Z","phase":"Phase 2","brief_title":"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer","source_id_and_acronym":"NCT03598257","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-17"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"0259c6da-60cc-4165-a7fc-adacc10727ab","acronym":"NCI-2018-00438","url":"https://clinicaltrials.gov/study/NCT03552471","created_at":"2021-01-18T17:29:09.671Z","updated_at":"2025-02-25T15:10:50.793Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03552471 - NCI-2018-00438","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 06/24/2022","primary_completion_date":" 06/24/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2025-02-13"},{"id":"759667ed-3d93-4013-b60b-a6259ed986b1","acronym":"MCC-21113","url":"https://clinicaltrials.gov/study/NCT05316129","created_at":"2022-04-07T13:56:37.707Z","updated_at":"2025-02-25T15:12:44.059Z","phase":"Phase 1","brief_title":"Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05316129 - MCC-21113","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["PD-L1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e liraltagene autoleucel (lira-cel)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"a68faa2b-d426-44af-a80f-b0fc99a1c7cd","acronym":"NXP800-101","url":"https://clinicaltrials.gov/study/NCT05226507","created_at":"2023-04-14T16:03:28.481Z","updated_at":"2025-02-25T15:12:35.833Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer","source_id_and_acronym":"NCT05226507 - NXP800-101","lead_sponsor":"Nuvectis Pharma, Inc.","biomarkers":" ARID1A • BRCA","pipe":" | ","alterations":" ARID1A mutation • BRCA mutation","tags":["ARID1A • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NXP800"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"},{"id":"aba0c228-f58a-4822-93bc-d017af087c85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887609","created_at":"2023-06-05T15:07:17.114Z","updated_at":"2025-02-25T15:13:30.894Z","phase":"Phase 2","brief_title":"An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","source_id_and_acronym":"NCT05887609","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"cf2cfcd4-c077-4397-9d63-381c2282ddc5","acronym":"TATCIST","url":"https://clinicaltrials.gov/study/NCT05219500","created_at":"2022-02-05T18:28:39.147Z","updated_at":"2025-02-25T15:12:35.305Z","phase":"Phase 2","brief_title":"Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I\u0026T of Castration-resISTant Prostate Cancer (TATCIST).","source_id_and_acronym":"NCT05219500 - TATCIST","lead_sponsor":"Fusion Pharmaceuticals Inc.","biomarkers":" MSI • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FPI-2265"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-13"},{"id":"e6f97d77-39cb-48b3-b840-079cf2a66ab1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00040222","created_at":"2021-01-18T00:02:42.489Z","updated_at":"2025-02-25T15:09:35.129Z","phase":"","brief_title":"Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer","source_id_and_acronym":"NCT00040222","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 377","initiation":"Initiation: 07/01/2002","start_date":" 07/01/2002","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-13"},{"id":"4a93fa9c-cccb-4098-a7be-8644c6938000","acronym":"SOLO-1","url":"https://clinicaltrials.gov/study/NCT01844986","created_at":"2021-01-17T17:30:05.211Z","updated_at":"2025-02-25T15:17:06.143Z","phase":"Phase 3","brief_title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","source_id_and_acronym":"NCT01844986 - SOLO-1","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/26/2013","start_date":" 08/26/2013","primary_txt":" Primary completion: 05/17/2018","primary_completion_date":" 05/17/2018","study_txt":" Completion: 08/29/2028","study_completion_date":" 08/29/2028","last_update_posted":"2025-02-12"},{"id":"9b56a9a0-f770-4d39-8edb-abcea82a2a26","acronym":"GENRE2","url":"https://clinicaltrials.gov/study/NCT04474834","created_at":"2021-01-18T21:29:47.073Z","updated_at":"2025-02-25T15:18:44.876Z","phase":"","brief_title":"Genetic Risk Estimations for Influencing Decision Making in Women At High Risk of Breast Cancer, GENRE 2 Study","source_id_and_acronym":"NCT04474834 - GENRE2","lead_sponsor":"Mayo Clinic","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 900","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 12/15/2029","primary_completion_date":" 12/15/2029","study_txt":" Completion: 12/15/2029","study_completion_date":" 12/15/2029","last_update_posted":"2025-02-12"},{"id":"354295c1-22c1-46a8-9795-aed719694630","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942300","created_at":"2023-07-12T15:08:55.008Z","updated_at":"2025-02-25T15:28:10.507Z","phase":"Phase 1","brief_title":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05942300","lead_sponsor":"Lan Coffman","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-11"},{"id":"0a8d6efe-c307-457d-99f7-770545d57f94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02631733","created_at":"2021-01-18T12:47:51.838Z","updated_at":"2025-02-25T15:25:24.826Z","phase":"Phase 1","brief_title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","source_id_and_acronym":"NCT02631733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 11/21/2019","primary_completion_date":" 11/21/2019","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2025-02-10"},{"id":"e26650cf-8309-4e3f-ba36-361dadb2b1b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595905","created_at":"2021-01-17T17:31:58.977Z","updated_at":"2025-02-25T16:36:40.508Z","phase":"Phase 2","brief_title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","source_id_and_acronym":"NCT02595905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 333","initiation":"Initiation: 09/15/2016","start_date":" 09/15/2016","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2025","study_completion_date":" 03/15/2025","last_update_posted":"2025-02-06"},{"id":"4a2584c4-8793-4aef-afa0-b4aee3f5f1c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06324240","created_at":"2024-03-21T20:40:15.862Z","updated_at":"2025-02-25T16:47:36.765Z","phase":"Phase 1","brief_title":"Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer","source_id_and_acronym":"NCT06324240","lead_sponsor":"Emory University","biomarkers":" PD-L1 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" PD-L1 expression • BRCA mutation","tags":["PD-L1 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-05"},{"id":"9de11c0f-2cdb-4547-9a51-ea4c6912c584","acronym":"WoO","url":"https://clinicaltrials.gov/study/NCT04644289","created_at":"2021-01-19T20:39:18.066Z","updated_at":"2025-02-25T16:53:24.058Z","phase":"Phase 2","brief_title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","source_id_and_acronym":"NCT04644289 - WoO","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA • CTLA4","pipe":" | ","alterations":" PD-L1 expression • BRCA mutation","tags":["BRCA • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-04"},{"id":"ae36f3a0-eb85-44ba-afee-09efb5463d1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434316","created_at":"2021-01-18T05:55:48.375Z","updated_at":"2025-02-25T16:51:08.574Z","phase":"Phase 1","brief_title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01434316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • dinaciclib (MK-7965)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/11/2011","start_date":" 11/11/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-04"},{"id":"0a161a88-300c-46f6-886d-a1fdcd0ce1df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02158507","created_at":"2021-01-18T10:02:31.452Z","updated_at":"2025-02-25T13:11:14.212Z","phase":"","brief_title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT02158507","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 09/04/2014","start_date":" 09/04/2014","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 07/22/2021","study_completion_date":" 07/22/2021","last_update_posted":"2025-02-03"}]